Disease/Infection News

RSS

NIAID awards approximately $36.3 million to fuel vaccine research for coronaviruses

The National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health, has awarded approximately $36.3 million to three academic institutions to conduct research to develop vaccines to protect against multiple types of coronaviruses and viral variants.

28 Sep 2021

Study finds common adverse events between Flu and COVID-19 vaccines

A study compared the top 10 common adverse events of COVID-19 vaccines and flu vaccine’s adverse effects.

28 Sep 2021

COVID-19 vaccination reduces risk and duration of SARS-CoV-2 infection

In a study conducted at the European Institute of Oncology, scientists have found that the risk and duration of SARS-CoV-2 infection reduced significantly after COVID-19 vaccination.

28 Sep 2021

Caspase-11 identified as regulator of inflammatory pathology in SARS-CoV-2 infections

New findings identify CASP4/11 as detrimental to inflammation and coagulopathy associated with SARS-CoV-2 infection.

28 Sep 2021

Scientists create new compliance-based model for SARS-CoV-2 transmission

Researchers from Utrecht University have been investigating the interactions between compliance social distance measurements, infection, and vaccination coverage in order to inform public health policy further. A research paper covering their work is available on the medRxiv* preprint server.

28 Sep 2021

Super-resolution imaging and size analysis of SARS-CoV-2 virus particles

Researchers from the University of Oxford and the University of Warwick have collaborated to develop a method to better understand and evaluate these pleiomorphisms.

28 Sep 2021

Study shows link between smoking and COVID-19 severity, death

Smoking is highly likely to worsen the severity of COVID-19 and the risk of dying from the infection, finds a large UK Biobank study published online in the respiratory journal Thorax.

28 Sep 2021

Evidence of persisting autoreactivity in post-acute sequelae of SARS-CoV-2 infection?

It has been demonstrated in recent studies that there is a significant breadth of emerging autoreactivity associated with severe severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. More specifically, researchers from Emory University have identified a relaxation of peripheral tolerance within early antibody secretion cells that arise in individuals infected with SARS-CoV-2, as important drivers of those responses.

28 Sep 2021

Novel polyclonal antibody therapy meets the criteria for graduation to phase 3 in ACTIV-2 trial

The AIDS Clinical Trials Group (ACTG), the largest global HIV research network, which recently expanded its focus to include evaluating outpatient treatment for COVID-19, today announced that SAB-185, a novel polyclonal antibody therapy, has demonstrated safety and efficacy in phase 2 that meet the criteria for graduation to phase 3 in the ACTIV-2 Outpatient Monoclonal Antibodies and Other Therapies Trial (ACTG A5401).

28 Sep 2021

Risk factors associated with in-school transmission of SARS-CoV-2

As schools resume in the United States and COVID-19 cases amongst children begin to rise, a new study published on the medRxiv* preprint server has highlighted the risk factors for in-school transmission of COVID-19. They also provide evidential support for the layered prevention strategies in schools settings.

28 Sep 2021

COVID Moonshot receives key funding to accelerate drug discovery efforts

The COVID Moonshot, a non-profit, open-science consortium of scientists from around the world dedicated to the discovery of globally affordable and easily-manufactured antiviral drugs against COVID-19 and future viral pandemics has received key funding of £8 million from Wellcome, on behalf of the Covid-19 Therapeutics Accelerator.

28 Sep 2021

Confinement drastically reduced the transmission of COVID-19 variants in Spain during first wave

The most complete studies on the variants of the coronavirus that dominated the first waves in Spain have just been published in Nature Genetics. The study was carried out by the SeqCOVID consortium, which includes more than 50 Spanish institutions led by the University of Valencia, the Institute of Biomedicine of Valencia (IBV, CSIC), and the Fisabio Foundation.

28 Sep 2021

Scientists identify potential antibody candidate with broad-spectrum neutralizing efficacy against SARS-CoV-2 variants

A team of scientists from China and the USA has recently described the antiviral efficacy of a monoclonal antibody candidate targeting the spike receptor-binding domain (RBD) of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Importantly, they have observed that emerging spike mutations could not affect the potency of this antibody. The study is currently available on the bioRxiv* preprint server.

27 Sep 2021

Pfizer-BioNTech’s COVID-19 vaccine appears effective against SARS-CoV-2 mu variant

Researchers in Japan have conducted a study showing that the vaccine developed by Pfizer-BioNTech to protect against coronavirus disease 2019 (COVID-19) seems to be adequately effective against the B.1.621 (mu) variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

27 Sep 2021

UK's top rugby players support COVID-19 vaccine roll out

Some of the country's top rugby players have today (Tuesday 28 September) encouraged young people to get their COVID-19 vaccine as they discuss their personal experiences of the pandemic.

27 Sep 2021

Researchers discover protein previously unknown to be involved in SARS-CoV-2 infection

Researchers in the UK and Germany have provided evidence for a novel mechanism by which severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – the agent that causes coronavirus disease 2019 (COVID-19) – binds to human host cells.

27 Sep 2021

Enterovirus 71 vaccine candidate strains exhibit good immunogenicity and cross-neutralization activity

Announcing a new article publication for Zoonoses journal. In this commentary researchers from Beijing Minhai Biotechnology Co., Ltd., Beijing, China, Hubei Provincial Center for Disease Control and Prevention, Wuhan, China, Guangdong Provincial Institute of Biological Products and Drugs, Guangzhou, China, Gaozhou Center for Disease Control and Prevention, Guangdong, China and the Yangchun Center for Disease Control and Prevention, Guangdong, China consider immungenicity and cross-neutralizing activity of enterovirus 71 vaccine candidate strains.

27 Sep 2021

Researchers investigate dynamic changes in mosquitoes and their viromes in Wuhan during 2020

Announcing a new article publication for Zoonoses journal. Researchers from Key Laboratory of Special Pathogens and Biosafety, Wuhan Institute of Virology, Wuhan, China, University of Chinese Academy of Sciences, Beijing, China, Jinan University, Shenzhen, China and Shanghai Jiao Tong University School of Medicine, Shanghai, China consider dynamic surveillance of mosquitoes and their viromes in Wuhan during 2020.

27 Sep 2021

An in-depth assessment into origin and spread of SARS-CoV-2 Delta variant in Brazil

Brazilian researchers characterize the dissemination of the Delta VOC in Brazil and assess its emergence within the global Delta phylogeny.

27 Sep 2021

Third COVID-19 mRNA vaccine booster dose indicated for myelofibrosis patients

A new study discusses the utility of a third booster dose in patients with myelofibrosis.

27 Sep 2021

Disease/Infection News

NIAID awards approximately $36.3 million to fuel vaccine research for coronaviruses

Study finds common adverse events between Flu and COVID-19 vaccines

COVID-19 vaccination reduces risk and duration of SARS-CoV-2 infection

Caspase-11 identified as regulator of inflammatory pathology in SARS-CoV-2 infections

Scientists create new compliance-based model for SARS-CoV-2 transmission

Super-resolution imaging and size analysis of SARS-CoV-2 virus particles

Study shows link between smoking and COVID-19 severity, death

Evidence of persisting autoreactivity in post-acute sequelae of SARS-CoV-2 infection?

Novel polyclonal antibody therapy meets the criteria for graduation to phase 3 in ACTIV-2 trial

Risk factors associated with in-school transmission of SARS-CoV-2

COVID Moonshot receives key funding to accelerate drug discovery efforts

Confinement drastically reduced the transmission of COVID-19 variants in Spain during first wave

Scientists identify potential antibody candidate with broad-spectrum neutralizing efficacy against SARS-CoV-2 variants

Pfizer-BioNTech’s COVID-19 vaccine appears effective against SARS-CoV-2 mu variant

UK's top rugby players support COVID-19 vaccine roll out

Researchers discover protein previously unknown to be involved in SARS-CoV-2 infection

Enterovirus 71 vaccine candidate strains exhibit good immunogenicity and cross-neutralization activity

Researchers investigate dynamic changes in mosquitoes and their viromes in Wuhan during 2020

An in-depth assessment into origin and spread of SARS-CoV-2 Delta variant in Brazil

Third COVID-19 mRNA vaccine booster dose indicated for myelofibrosis patients

How agentic AI is reshaping laboratory workflows

Fourier 80: bringing benchtop NMR systems to the laboratory

How industrial hygiene flow calibration supports defensible exposure data

Latest News